Arena Pharmaceutical (ARNA+1.4%) trades in the green today after earlier disclosing the price for a 60-day supply of Belviq 10-mg tablets at $199.50. This compares with Vivus' (VVUS+1%) Qsymia, which retails for $160 per month at a medium dose and $220 per month for the higher dose. Analysts note the success of Belviq will largely depend on lower co-payments and broader insurance coverage, which could come in the next two years.